Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree

Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree

Episode 213

Together, Roche and Biogen paid over $5.5 billion for gene therapy companies Spark and Nightstar. What does this mean for the emerging technology? Spark, of course, received FDA approval for Luxturna as a treatment for inherited retinal disease. But the drug isn’t Roche’s primary focus. Meanwhile, Nightstar’s clinical-stage products could give Biogen a second shot at a gene therapy portfolio after the company severed ties with AGTC in December. Could Biogen make a move to bulk up its ophthalmology offerings?

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the OIS podcast, please complete the application today.

Meet Our New Host

EHSAN SADRI

Sadri_Ehsan

Joining the company in 2019, to create and manage a new line of podcasts, publications, and other editorial products.

Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.